Valuation: Novartis

Market Cap 291B 255B 234B 218B 414B 27,752B 420B 2,811B 1,093B 13,642B 1,094B 1,071B 47,008B P/E 2026 *
22.2x
P/E 2027 * 18.8x
Enterprise Value 324B 283B 260B 242B 460B 30,819B 467B 3,122B 1,214B 15,149B 1,215B 1,189B 52,204B EV / Sales 2026 *
5.69x
EV / Sales 2027 * 5.3x
Free-Float
91.66%
Yield 2026 *
2.76%
Yield 2027 * 2.85%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 68 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
+1.84%+0.12%-4.18%-33.64% 139B
Average +2.31%+5.27%+27.74%+49.54% 394.03B
Weighted average by Cap. +2.42%+6.12%+41.26%+81.76%

Financials

2026 *2027 *
Net sales 56.91B 49.75B 45.72B 42.62B 80.84B 5,419B 82.06B 549B 213B 2,664B 214B 209B 9,179B 60.37B 52.78B 48.5B 45.21B 85.75B 5,748B 87.05B 582B 226B 2,825B 227B 222B 9,736B
Net income 14.15B 12.37B 11.37B 10.6B 20.1B 1,348B 20.41B 137B 53.07B 662B 53.13B 51.99B 2,283B 15.74B 13.76B 12.64B 11.78B 22.35B 1,498B 22.69B 152B 59B 736B 59.06B 57.8B 2,538B
Net Debt 32.22B 28.16B 25.88B 24.12B 45.76B 3,067B 46.45B 311B 121B 1,508B 121B 118B 5,196B 28.72B 25.11B 23.07B 21.51B 40.79B 2,734B 41.41B 277B 108B 1,344B 108B 105B 4,632B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA